Clearbridge Health

Clearbridge Health in private placement to raise $11.3 mil to speed up Asia growth plans

SINGAPORE (July 29): Clearbridge Health is raising $11.34 million from a share placement exercise to accelerate its growth plans in Asia’s healthcare market.

Under the terms of the share placement agreement, Clearbridge, will issue some 80.5 million new ordinary shares at 14.1 cents each.

This is a discount of 9.96% to its volume weighted average price of 15.66 cents each, for all trade trades done on Catalist on Friday, the full market day before which the placement agreements were signed.

Clearbridge acquires 89.6% stake in Indonesia's IGM Labs for $9.4 mil

SINGAPORE (Apr 3): Clearbridge Health is acquiring a 89.6% stake in IGM Labs of Indonesia for $9.4 million or 2.8 times its EV/EBITDA.

See also: Clearbridge Health started at ‘buy’ with 28 cents target by Phillip on growth trajectory

The sale and purchase agreement was signed between Clearbridge’s wholly-owned subsidiary SAM Laboratory and seller PT Kreasi Putra Nusantara.

Clearbridge subsidiary to issue $2 mil in convertible bonds

SINGAPORE (Mar 25): Clearbridge Health Limited’s subsidiary, Clearbridge Biophotonics, is set to issue $2 million in convertible bonds to develop its proprietary computational imaging microscopy technology with the aim of commercialisation.  

Enterprise Singapore’s investment arm SEEDS Capital will subscribe for $1 million of the convertible bonds.

At the same time, Clearbridge’s wholly owned subsidiary Clearbridge BSA will convert existing loans to Clearbridge Biophotonics for another $1 million of the convertible bonds.

Biolidics shares slump on Catalist debut

SINGAPORE (Dec 19): Just two hours into its debut on the Singapore Exchange (SGX) Catalist board, shares in medical technology firm Biolidics have slumped 23.2% from its listing price of 28 cents.

The stock on Wednesday opened 5.4% lower than its IPO price at 26.5 cents. As at 11.15am, Biolidics is trading at 21.5 cents, with some 4 million shares having changed hands.

Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing

SINGAPORE (Dec 11): Medtech company Biolidics is selling 27.5 million new shares at 28 cents each to retail and institutional investors in a private placement ahead of its listing on the Catalist Board of the Singapore Exchange.

See: Clearbridge Health associate Biolidics lodges prelim prospectus

Clearbridge Health rides on China's biotech boom for cancer diagnostic spinoff

SINGAPORE (Aug 31): Investors and foreign biotech veterans are making their way to China as the government aims to build a healthcare empire.

Jeremy Yee, former CEO of Cordlife Group and now running his second healthcare company Clearbridge Health, hopes to tap into that optimism. He plans to spin off a cancer diagnostics associate company that is aiming to expand into China, and buy more testing laboratories in the region. Yee hopes these moves will help revive investor interest in Clearbridge.

Clearbridge enters MoU for expansion of lab testing services to Indonesia

SINGAPORE (Aug 23): Clearbridge Health’s wholly-owned subsidiary, SAM Laboratory, is acquiring a controlling stake in PT Indo Genesis Medika, a company incorporated in Indonesia, for an aggregate consideration of about IDR 40.7 billion ($3.8 million).

Under the memorandum of understanding (MoU) inked between SAM Lab, Indo Genesis and PT Kreasi Putra Nusantara (KPN), SAM Lab will subscribe for up to 49% of Indo Genesis for IDR 26.6 billion, with KPN holding the remaining 51% in the company.

Clearbridge BioMedics receives $6.6 mil in pre-IPO funding ahead of targeted 4Q launch

SINGAPORE (June 28): Clearbridge BioMedics has announced $6.6 million in pre-initial public offering (IPO) funding from oncology medical professionals, as well as investors focused in healthcare & biotechnology.

The company expects to launch its IPO in 4Q18.

In a Thursday announcement, the clinical stage cancer diagnostics company says it intends to use its latest round of funds for business expansion, technology development, talent recruitment and IPO-related expenses to develop end-to-end cancer diagnostic tests.

Clearbridge Health acquires 85% stake in medical aesthetics clinic for $5.5 mil

SINGAPORE (Apr 3): Clearbridge Health, the recently listed healthcare group, announced that it has completed its acquisition of an 85% stake in Medic Surgical Private Limited (MSPL) and Medic Laser Private Limited (MLPL) for $5.5 million.

See: Clearbridge closes flat at 28 cents on trading debut

Clearbridge closes flat at 28 cents on trading debut

SINGAPORE (Dec 18): Shares of Clearbridge Health closed flat at its initial public offering (IPO) price of 28 cents in its trading debut on Monday, even as some 9.3 million shares changed hands during the day – putting it among one of the most active stocks.

During the day, shares in the healthcare company rose as much as 2 cents, or 7.1%, to 30 cents.

Be informed of the stories that matter